Inactive Instrument

GeneNews Ltd Share Price Toronto S.E.

CA36870T2065

Biotechnology & Medical Research

StageZero Life Sciences, Ltd. is an integrated healthcare company focused on enhancing the early detection and management of cancer and chronic diseases through advanced molecular diagnostics and clinical interventions. It is developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and for personalized health management, with an initial focus on cancer-related indications. The Company offers early cancer diagnostics and risk stratification via Aristotle, using messenger Ribonucleic Acid (mRNA) technology to identify the molecular signatures of multiple cancer types. Its Care Oncology Clinic provides the COC Protocol, a supervised treatment regimen designed to target multiple metabolic cancer pathways, complementing standard cancer therapies by limiting cancer cell energy supply and use. Additionally, COC offers AVRT, a physician-led telehealth program dedicated to identifying and managing early warning signs of cancer and chronic diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	4.21M 3.69M 3.43M 3.15M 5.93M 407M 6.03M 40.81M 15.97M 199M 15.81M 15.47M 687M	P/E 2021	-2.2x	P/E 2022	-0.39x
Enterprise Value	6M 5.26M 4.89M 4.49M 8.45M 579M 8.58M 58.1M 22.73M 283M 22.51M 22.03M 978M	EV / Sales 2021	3.99x	EV / Sales 2022	1.66x
Free-Float	79.62%	Yield 2021 *	-	Yield 2022	-

13/05/25	StageZero Life Sciences, Ltd. and ElevationMD Introduce Aristotle and AVRT for the Early Detection of Cancer	CI
06/05/25	StageZero Life Sciences Ltd. announced that it expects to receive CAD 2 million in funding	CI
16/12/24	StageZero Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
30/09/24	StageZero Life Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
21/05/24	StageZero Life Sciences Ltd., Q1 2024 Earnings Call, May 21, 2024
16/05/24	StageZero Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/11/23	StageZero Life Sciences Ltd., Q3 2023 Earnings Call, Nov 15, 2023
14/11/23	StageZero Life Sciences Ltd. Partners with My One Medical Source and 1,000+ Medical Access Points in the USA	CI
13/11/23	StageZero Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
07/11/23	StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer Offerings	CI
20/10/23	StageZero Life Sciences	MT
20/10/23	Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer Offerings	CI
15/08/23	StageZero Life Sciences Ltd., Q2 2023 Earnings Call, Aug 15, 2023

01-21	StageZero Announces Partial Revocation of Failure to File Cease Trade Order and Proposed Financing	AQ
14/08/25	StageZero Announces Listing on the NEX Exchange	AQ
25/07/25	StageZero Announces Delisting from the TSX and a Concomitant Application for Listing on the NEX Exchange	AQ
13/05/25	StageZero Life Sciences and ElevationMD Introduce Aristotle and AVRT for the Early Detection of Cancer	AQ
07/05/25	StageZero Announces Partial Revocation of Cease Trade Order and Proposed Financing	AQ

Manager	Title	Age	Since
James Howard-Tripp CEO	Chief Executive Officer	-	09/08/2016
Rebecca Greco IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Rory Riggs CHM	Chairman	72	31/12/1999
James Howard-Tripp CHM	Chairman	-	18/07/2013
Garth MacRae BRD	Director/Board Member	92	31/12/1999

GeneNews Ltd Share Price Toronto S.E.

Stocks

CA36870T2065

Biotechnology & Medical Research

Valuation: GeneNews Ltd

Latest news : GeneNews Ltd

Press Releases: GeneNews Ltd

Quotes and Performance

Managers and Directors: GeneNews Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENENEWS LTD	-5.00%	+26.09%	-	-	3.51M
LONZA GROUP AG	-4.89%	-7.90%	-4.49%	+9.27%	48.5B
REVOLUTION MEDICINES, INC.	-0.14%	-1.05%	+376.39%	+583.71%	38.97B
BEONE MEDICINES AG	+0.39%	+4.36%	+9.59%	+61.99%	35.43B
IQVIA HOLDINGS INC.	-1.54%	-4.48%	+24.89%	-13.03%	33.65B
CELLTRION, INC.	-0.87%	-1.56%	-1.43%	+29.16%	26.58B
ASCENDIS PHARMA A/S	-1.28%	-5.14%	-	-	16.82B
MEDPACE HOLDINGS, INC.	-0.67%	-1.50%	+70.98%	+115.31%	15.18B
EUROFINS SCIENTIFIC SE	+1.32%	+2.29%	+14.62%	+15.52%	13.89B
ICON PUBLIC LIMITED COMPANY	+0.40%	-0.41%	+19.80%	-31.98%	12.76B
Average	+0.65%	-1.21%	+63.79%	+96.24%	26.87B
Weighted average by Cap.	-0.11%	-1.28%	+76.11%	+121.29%

	2021	2022
Net sales	5.07M 4.44M 4.13M 3.79M 7.14M 489M 7.25M 49.1M 19.21M 239M 19.02M 18.61M 827M	3.8M 3.33M 3.09M 2.84M 5.35M 366M 5.43M 36.77M 14.38M 179M 14.24M 13.94M 619M
Net income	-7.48M -6.56M -6.1M -5.6M -10.54M -723M -10.71M -72.5M -28.36M -353M -28.09M -27.49M -1.22B	-11.42M -10.01M -9.3M -8.54M -16.08M -1.1B -16.34M -111M -43.26M -539M -42.84M -41.93M -1.86B
Net Debt	-368K -323K -300K -276K -519K -35.58M -527K -3.57M -1.4M -17.39M -1.38M -1.35M -60.12M	1.78M 1.56M 1.45M 1.33M 2.51M 172M 2.55M 17.29M 6.76M 84.2M 6.7M 6.55M 291M